The TT analogues with modest activity in K562 growth inhibition, translocation of PKC and subsequent downstream phosphorylation of signaling pathways, resulted only in an initial tumor volume reduction (i.e., EBC-147, Fig. 5E). The gene discussed is PRRT2; the disease is neoplasm.